Compare Amylx Pharmaceuticals Inc (AMLX) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.32 (market cap $75.52B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 38.1× Amylx Pharmaceuticals Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.4% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MDLZ | |
|---|---|---|
Market Cap | $1.98B | $75.52B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $70.75 |
52-Week Low | $7.64 | $51.51 |
Enterprise Value | $1.70B | $95.62B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Mondelez International (MDLZ) trades at $58.83, up 0.91% today, with a bearish technical signal but strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $0.67. Revenue grew to $38.54B in 2025, though net income margin compressed to 6.64%. Recent news highlights innovation in packaging and new product launches, alongside a stable dividend of $0.50 per share.
The outlook remains positive with a consensus price target of $68.33, implying 16% upside. Key opportunities include resilient snacking demand and strategic innovations, while risks involve margin pressure from input costs and competitive intensity. Institutional sentiment is bullish, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
